FDA, Ae­tion part­ner on re­al-world da­ta an­a­lyt­ics for Covid-19

The FDA on Tues­day said it will part­ner with New York-based health tech­nol­o­gy firm Ae­tion, Inc. to de­vel­op re­al-world da­ta an­a­lyt­ics to an­swer press­ing ques­tions re­lat­ed to coro­n­avirus dis­ease (Covid-19).

“Eval­u­a­tion of re­al-world da­ta has the po­ten­tial to pro­vide a wealth of rapid, ac­tion­able in­for­ma­tion to bet­ter un­der­stand dis­ease symp­toms, de­scribe and mea­sure im­mu­ni­ty and un­der­stand avail­able med­ical prod­uct sup­plies to help mit­i­gate po­ten­tial short­ages. These da­ta can al­so in­form on­go­ing work to eval­u­ate po­ten­tial ther­a­pies, vac­cines or di­ag­nos­tics for COVID-19,” said FDA Prin­ci­pal Deputy Com­mis­sion­er Amy Aber­nethy.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN